Patents Examined by Dylan C Jones
  • Patent number: 11920202
    Abstract: Described herein is an unbiased method of identifying tumor rejection mediating neoepitopes (TRMNs). Putative neoepitopes from a cancer cell exome sequence from a cancer patient are putative neoepitopes are unbiased by MHC binding and/or CD8T* reactivity. By plotting the putative neoepitope IC50s on one axis, and the non-mutated amino acid sequence IC50s on a perpendicular axis to provide a bivariate scatter plot, novel TRMNs are identified TRMNs the neoepitopes in the bivariate scatter plot which are in the space greater than 501 nM on the x-axis and greater than 501 nM on the y-axis. Peptides and nucleic acids for expressing peptides including the TRMNs are also described.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: March 5, 2024
    Assignee: UNIVERSITY OF CONNECTICUT
    Inventors: Pramod K. Srivastava, Ion I Mandoiu, Cory A Brennick, Mariam M George, Marmar Moussa
  • Patent number: 11845930
    Abstract: Methods and systems for CRISPR positive selection are described. CRISPR positive selection uses DNA sequencing to identify genes that their perturbation by CRISPR guide RNAs is correlated to the phenotype. In some aspects, disclosed are genome-wide CRISPR/Cas9 screening methods to identify genetic modifiers. Also disclosed are the apparatuses used for performing the methods.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: December 19, 2023
    Assignee: Regeneron Pharmaceuticals Inc.
    Inventors: Wen Fury, Yu Bai